Guidelines for interpreting HIV testing results

Similar documents
Suggested Reporting Language for the HIV Laboratory Diagnostic Testing Algorithm

INTERPRETATION INFORMATION SHEET

Hepatitis and Retrovirus. LIAISON XL Accurate detection of HIV infection. HIV Ab/Ag FOR OUTSIDE THE US AND CANADA ONLY

in hiv diagnostics the role of phls

HBV DNA < monitoring interferon Rx

Algorithm for detecting Zika virus (ZIKV) 1

LIAISON XL HCV Ab Accurate diagnosis of the early stage of HCV infection

HIV DIAGNOSIS: A GUIDE FOR SELECTING RAPID DIAGNOSTIC TEST (RDT) KITS

Diagnosis of HIV-1 Infection. Estelle Piwowar-Manning HPTN Central Laboratory The Johns Hopkins University

LAB 14 ENZYME LINKED IMMUNOSORBENT ASSAY (ELISA)

Types of HIV test. Antigen - Any substance (such as an immunogen or a hapten) foreign to the body that stimulates an immune system response.

(EMEA/CHMP/BWP/298390/2005)

SOGC recommendation on ZIKA virus exposure for clinicians caring for pregnant women and those who intend to get pregnant

LIAISON XL HBsAg Quant

How Does a Doctor Test for AIDS?

Guidelines for TB Blood Testing. Minnesota Department of Health TB Prevention and Control Program June 2011

Corporate Medical Policy Genetic Testing for Alpha-1 Antitrypsin Deficiency

Viral load testing. medical monitoring: viral load testing: 1

Quality Assurance Guidelines for Testing Using Rapid HIV Antibody Tests Waived Under the Clinical Laboratory Improvement Amendments of 1988

Lyme (IgG and IgM) Antibody Confirmation

Identifying Celiac Disease and Gluten Sensitivity with Minimally Invasive Testing

Body Fluid Exposure:

WHO Prequalification of Diagnostics Programme PUBLIC REPORT. Product: Genscreen ULTRA HIV Ag-Ab Number: PQDx Abstract

4A. Types of Laboratory Tests Available and Specimens Required. Three main types of laboratory tests are used for diagnosing CHIK: virus

CME Article Hiv Disease Surveillance

Background Information

510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

Antiretroviral therapy for HIV infection in infants and children: Towards universal access

Direct Testing Systems and Serology

Epstein Barr Virus (EBV) Serological Diagnosis of Epstein Barr Virus. Epstein Barr Virus (EBV) Epstein Barr Virus (EBV)

Understanding the Western Blot

Reducing the Diagnostic Window for Acute HIV

Laboratory Testing for Middle East Respiratory Syndrome Coronavirus

Syphilis Fast latex Agglutination Test: A Rapid Confirmatory Test for Syphilis

PROPOSED DOCUMENT. Global Harmonization Task Force. Title: Principles of In Vitro Diagnostic (IVD) Medical Devices Classification

Hepatitis C Virus Infection: Prevalence Report, 2003 Data Source: Minnesota Department of Health HCV Surveillance System

GLOBAL FUND QUALITY ASSURANCE POLICY FOR DIAGNOSTICS PRODUCTS. (Issued on 14 December 2010, amended on 5 February 2014)

Viral Hepatitis APHL survey report

Offering Testing for Hepatitis B and C in Primary Care

ALS and Lyme Disease Questions from Patient and Families Responses from Medical Experts

Notes. Complete childhood vaccination course (CCV) CCV and DTP booster as adolescent/adult within last 10 years

WHO/HIVRESNET HIV DRUG RESISTANCE LABORATORY STRATEGY

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

Bloodborne Pathogens (HIV, HBV, and HCV) Exposure Management

What is an IGRA? What is an IGRA? Are they available here? How do I use them? Learning Objectives

DEFINITIONS 3 REFERENCES... 47

U.S. Public Health Service Guidelines for Testing and Counseling Blood and Plasma Donors for Human Immunodeficiency Virus Type 1 Antigen

TUBERCULOSIS PLEURAL EFFUSION - MANAGEMENT

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016

NON-OCCUPATIONAL POST EXPOSURE PROPHYLAXIS FOR SEXUAL ASSAULT SURVIVORS. Carl LeBuhn, MD

Zika Virus. Fred A. Lopez, MD, MACP Richard Vial Professor Department of Medicine Section of Infectious Diseases

Tuberculosis Exposure Control Plan for Low Risk Dental Offices

AIR FORCE REPORTABLE EVENTS GUIDELINES & CASE DEFINITIONS

Appendix 3 Exposure Incident Report Form

Parvovirus B19 Infection in Pregnancy

Hepatitis C 1) THE DISEASE AND ITS EPIDEMIOLOGY

Borrelia burgdorferi IgG, IgM Fully automated chemiluminescence assays for quantitative determination of Borrelia antibodies in serum and CSF

LYME DISEASE. 2.5M specimen tests per year. 97% accuracy with Rockland tools

Early detection of HIV infection in infants and children

Viral Safety of Plasma-Derived Products

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND

CHU Liège (Belgium) Medical Microbiology Dr P. HUYNEN SEROLOGICAL DIAGNOSIS IN 2006 AND FUTURE PROSPECTS

Overview of CLIA-Waived Rapid HIV Tests and the HIV Rapid

BVD qpcr Bulk Milk Test

CAP Accreditation Checklists 2015 Edition

HIV SIMPLE/RAPID ASSAYS: OPERATIONAL CHARACTERISTICS

LCD L C-Reactive Protein High Sensitivity Testing (hscrp)

Coding and Billing for HIV Services in Healthcare Facilities

EXERCISE 5: ERYTHROCYTES SEDIMENTATION RATE - ESR, SED RATE

GUIDELINE DOCUMENT CERVICAL CANCER SCREENING IN SOUTH AFRICA 2015

Department of Transfusion Medicine and Immunohematology

Laboratory confirmation requires isolation of Bordetella pertussis or detection of B. pertussis nucleic acid, preferably from a nasopharyngeal swab.

Diagnosis and Treatment Regimes for Syphilis By Dr John Bannister

Biologic Air-Borne Particle Detection, Sampling, and Identification

Assertive outreach enhances hepatitis B vaccination for people who inject drugs in Melbourne, Australia

HIV/AIDS: General Information & Testing in the Emergency Department

Coding and Billing. Commonly Asked Questions. Physician Office Reimbursement Guideline Q1. A1. Q2. A2.

GUIDELINES FOR VIRAL HEPATITIS SURVEILLANCE AND CASE MANAGEMENT

Chapter 14 Urinalysis, Body Fluids and Other Specimens. Objectives:

Project Completion Report (PCR) User Guide

Tuberculosis and HIV/AIDS Co-Infection: Epidemiology and Public Health Challenges

Outpatient/Ambulatory Health Services

HIV ASSAYS: OPERATIONAL CHARACTERISTICS

PLUS MAY EQUAL. Flu-Like Symptoms SORE THROAT, SWOLLEN GLANDS, FEVER, JOINT AND MUSCLE ACHES

Hepatitis B Virus (Pregnancy) Investigation Guideline

Transcription:

1 Guidelines for interpreting HIV testing results Developed through consultation between the National and State Reference Laboratories in Australia Disclaimer: The information contained herein was developed through consultation and contains the majority consensus views of Australian laboratory scientists and their Directors.

2 Introduction At a recent NRL Workshop, a satellite meeting was held to discuss specific aspects of HIV testing algorithms and the subsequent reporting of results. A specific aim was to achieve consensus between views. It was decided at the meeting that those aspects achieving majority or unanimous consensus would be presented to laboratory directors for approval. The following slides show the goal of the meeting, relevant points of discussion and the consensus outcomes.

3 Aim To standardise algorithms for HIV supplemental testing, their interpretation and the comments accompanying HIV test results, between the State Reference Laboratories in Australia.

4 Goals To reach consensus on: Interpretation of HIV test results Comments issued with laboratory reports on HIV testing Reporting WB indeterminate results The recommended interval between initial and follow-up samples The use of HIV Proviral DNA PCR in HIV confirmatory testing algorithms

5 Methods (1) The NRL conducted a survey of the participants in its anti-hiv external quality assessment scheme with a view to determining the range of comments used to interpret anti-hiv testing results for diagnostic purposes in Australia. The survey was presented as a set of nine testing result scenarios and laboratories were asked to provide the interpretive comments they would use for each of the scenarios.

6 Methods (2) Based on the survey results, the NRL developed a proposed algorithm and standard interpretive comments, including recommended intervals between initial and follow-up testing. These were circulated to all Australian laboratories conducting HIV confirmatory testing for their comment. Interested parties met to discuss the outcomes at the NRL Workshop. The algorithms developed from the discussion at the Workshop follow in slides 13 19. Slides 7 12 include specific discussions in the development of the algorithms.

7 Discussion (1) Australian laboratories conducting HIV confirmatory testing test differing populations. While some laboratories test individuals attending STD and/or IDU clinics, others test populations including very few from these specific groups at higher risk of HIV infection. Hence the confirmatory testing laboratories preferred a low risk algorithm to be available for those individuals being tested who are known to be at low risk for HIV infection. Laboratories are advised to use the low-risk strategy with caution. HIV infection in individuals with no declared risk or exposure occurs, sometimes more often than may be expected.

8 Discussion (2) In Australia, WB indeterminate reactivity was described by patterns of reactivity in 1987. These patterns were divided into groupings that have assisted with the interpretation of WB profiles. These groupings are still used today. They are: WB negative: No reactivity to viral proteins WB positive: Reactivity to glycoproteins and three other viral proteins

9 Discussion (3) WB indeterminate group 1: Reactivity to viral proteins, but not to p18, p24 or any envelope glycoproteins WB indeterminate group 2: Reactivity to viral proteins including p18, but not to p24 or any envelope glycoproteins

10 Discussion (4) WB indeterminate group 3: Reactivity to viral proteins including p24 but not to any envelope glycoproteins WB indeterminate group 4: Reactivity to envelope glycoproteins but to less than three other viral proteins

11 Discussion (5) Because each of the algorithms under consideration include p24 immunoassay (IA) supplemental testing, they can apply equally to situations where antigen/antibody combination or antibody only IAs are used for screening. The algorithms assume that confirmatory testing always includes WB. When results of serological testing on a sample indicate that a repeat collection is necessary, the consensus recommended interval between the first and second specimens was 6 weeks. However, all WB indeterminate reactivity should be followed up for 12 weeks (slides 18 and 19).

12 Discussion (6) Since this consultation the production of the only commercial assay for detection of HIV DNA has been discontinued. Caution should be exercised when interpreting HIV test results from an individual who received treatment early in infection. Seroconversion fulfilling the criteria for positive WB may be delayed or incomplete.

13 Results The results of the consultative process are shown on the following slides, where the following key is used: Green = Test results Yellow = Anti-HIV status reported Blue = Test used White = Comments included on report Italicised comments are discretionary

Result scenario following negative results on anti-hiv1/2 immunoassay Anti-HIV-1/2 IA*: neg (IA performed on a single aliquot of a sample) Negative If the sample were collected less than 12 weeks after exposure, this result may not exclude infection with HIV-1/2. * IA = immunoassay

Result scenario (1) following RR* on anti-hiv1/2 immunoassay (Risk high or unknown) HIV-1/2 WB neg, p24 Ag IA neg No status reported Reactivity in screening assay could not be confirmed by supplemental testing. Please submit follow-up sample 6 weeks after the index sample was collected. DNA PCR (for resolution in < 6 weeks) IA, ( supplemental testing if IA RR) * RR = repeatedly reactive

16 Result scenario (2) following RR on anti-hiv1/2 immunoassay Known low risk / no suspicion of seroconversion HIV-1 WB neg (+/- p24 IA Ag neg) Negative If the sample were collected less than 12 weeks after exposure, this result may not exclude infection with HIV 1/2.

17 Result scenario (3) following RR on anti-hiv1/2 immunoassay HIV-1 WB pos Anti-HIV-1 pos Please submit another sample to confirm the positive status of this individual.

Result scenario (4) following RR on anti-hiv1/2 immunoassay WB indeterminate groups I & 2 p24 Ag IA pos Anti-HIV-1 indeterminate DNA PCR for resolution in in <6 weeks. p24 Ag IA neg Anti-HIV-1 indeterminate p24 Ag IA neg (Low risk) Please submit another sample 6 weeks after the index sample. HIV-1 WB pos Anti-HIV-1 pos This indeterminate WB pattern commonly occurs in uninfected individuals owing to the presence of non-specific antibodies. Please submit another sample 6 weeks after the index sample was collected WB profile unchanged Anti-HIV-1 neg After 12 weeks follow-up Anti-HIV-1 neg If the sample were collected less than 12 weeks after exposure, this result may not exclude infection with HIV. Please submit another sample to confirm the positive status of this individual. This individual has had sufficient follow-up and is now considered anti-hiv negative unless indicated by risk, exposure or symptoms.

Result scenario (5) following RR on anti-hiv1/2 immunoassay WB indeterminate groups 3 & 4 p24 Ag IA neg Anti-HIV-1 indeterminate DNA PCR (for resolution in < 6 weeks.) p24 Ag IA pos Anti-HIV-1 indeterminate This indeterminate WB pattern may occur in uninfected individuals but may also be seen in early infection. Please submit another sample 6 weeks after the index sample was collected. Reactivity highly suggestive of HIV infection. Please submit another sample immediately. WB profile unchanged p24 neg HIV-1 WB pos After 12 weeks follow-up Anti-HIV-1 neg This individual has had sufficient follow-up and is now considered anti-hiv negative unless indicated by risk, exposure or symptoms. Anti-HIV-1 pos